ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants

ClinicalTrials.gov ID: NCT02737501

Public ClinicalTrials.gov record NCT02737501. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 8:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer

Study identification

NCT ID
NCT02737501
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Ariad Pharmaceuticals
Industry
Enrollment
275 participants

Conditions and interventions

Interventions

  • Brigatinib Drug
  • Crizotinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 25, 2016
Primary completion
Jul 27, 2020
Completion
Jan 28, 2021
Last update posted
Aug 19, 2021

2016 – 2021

United States locations

U.S. sites
12
U.S. states
11
U.S. cities
12
Facility City State ZIP Site status
USOR - Arizona Oncology Associates - Sedona Sedona Arizona 86336
Kaiser Permanente Bellflower Medical Offices Bellflower California 90706
University of Colorado Cancer Center Aurora Colorado 80045
Rocky Mountain Cancer Centers - Boulder Boulder Colorado 80303-1385
Sylvester Comprehensive Cancer Center Deerfield Beach Florida 33442
Beth Israel Deaconess Medical Center Boston Massachusetts 02215
West Michigan Cancer Center Kalamazoo Michigan 49007
Minnesota Oncology Coon Rapids Minnesota 55433
Montefiore Medical Center The Bronx New York 10461
Oncology Hematology Care - Blue Ash Cincinnati Ohio 45242-5665
Stephenson Cancer Center Oklahoma City Oklahoma 73104
Virginia Cancer Specialists - Fairfax Office Fairfax Virginia 22031

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 79 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02737501, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 19, 2021 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02737501 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →